{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:26Z","timestamp":1784557046120,"version":"3.55.0"},"reference-count":23,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"\n Summary<\/jats:title>\n \n Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by the destruction of the pancreatic beta cells, which produce insulin. Individuals with T1DM usually require at least 3-5 years to develop microvascular complications in comparison to people with type 2 diabetes (T2DM), who may develop complications even before the diagnosis of diabetes. We discuss a patient who presented with proliferative diabetic retinopathy subsequently diagnosed with T1DM and diabetic neuropathy following investigations. Diabetic retinopathy or other microvascular complications as the presenting feature of T1DM is rarely known or reported in the literature. A 33-year-old healthcare worker had been seen by the opticians due to 1-week history of blurred vision. The ophthalmology assessment had confirmed proliferative retinopathy in the right eye and severe non-proliferative retinopathy in the left eye with bilateral clinically significant macular oedema. His BMI was 24.9 kg\/m\n 2<\/jats:sup>\n . The nervous system examination revealed bilateral stocking type peripheral neuropathy. The random venous glucose was 24.9 mmol\/L. Plasma ketones were 0.7 mmol\/L and HbA1c was 137 mmol\/mol. On further evaluation, the anti-glutamic acid decarboxylase (GAD) antibody was positive, confirming the diagnosis of T1DM. He was started on aflibercept injections in both eyes, followed by panretinal photocoagulation. Subsequent nerve conduction studies confirmed the presence of symmetrical polyneuropathy. The pathogenesis of the development of microvascular complications in T1DM is multifactorial. Usually, the development of complications is seen at least a few years following the diagnosis. The occurrence of microvascular complications at presentation is rare. This makes the management challenging and extremely important in preventing the progression of the disease.\n <\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n The pathogenesis of the development of microvascular complications in type 1 diabetes mellitus is multifactorial.<\/jats:p>\n <\/jats:list-item>\n \n The development of complications is seen at least a few years following the diagnosis.<\/jats:p>\n <\/jats:list-item>\n \n Occurrence of microvascular complications at presentation is rare.<\/jats:p>\n <\/jats:list-item>\n \n This makes the management challenging and extremely important to prevent the progression of the disease.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-22-0406","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T06:48:24Z","timestamp":1702882104000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":0,"title":["Proliferative diabetic retinopathy as the initial presenting feature of type 1 diabetes"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-5309","authenticated-orcid":true,"given":"Ishara","family":"Ranathunga","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, North Cumbria Integrated Care NHS Foundation Trust, Whitehaven, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandima","family":"Idampitiya","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, North Cumbria Integrated Care NHS Foundation Trust, Whitehaven, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Endocrine Connections","first-page":"R38","article-title":"On type 1 diabetes mellitus pathogenesis","volume":"7","author":"Paschou","year":"2018","unstructured":"Paschou SAPapadopoulou-Marketou NChrousos GP & Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocrine Connections20187R38\u2013R46. (https:\/\/doi.org\/10.1530\/EC-17-0347)"},{"key":"bib2","series-title":"Current Pharmaceutical Design","first-page":"2279","article-title":"Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy","volume":"11","author":"Yamagishi","year":"2005","unstructured":"Yamagishi S & Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design2005112279\u20132299. (https:\/\/doi.org\/10.2174\/1381612054367300)"},{"key":"bib3","series-title":"MMWR","first-page":"1044","article-title":"Awareness of family health history as a risk factor for disease\u2013United States, 2004","volume":"53","year":"2004","unstructured":"Centers for Disease Control and Prevention (CDC). Awareness of family health history as a risk factor for disease\u2013United States, 2004 [Internet]. MMWR2004531044\u20131047. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15538320"},{"key":"bib4","series-title":"Genes","article-title":"Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis","volume":"8","author":"St\u00f8rling","year":"2017","unstructured":"St\u00f8rling J & Pociot F. Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis. Genes20178. (https:\/\/doi.org\/10.3390\/genes8020072)"},{"key":"bib5","series-title":"Endocrine","first-page":"42","article-title":"Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination","volume":"78","author":"Aydo\u011fan","year":"2022","unstructured":"Aydo\u011fan B\u0130\u00dcnl\u00fct\u00fcrk U & Cesur M. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination. Endocrine20227842\u201346. (https:\/\/doi.org\/10.1007\/s12020-022-03130-8)"},{"key":"bib6","series-title":"Journal of Diabetes Investigation","first-page":"1290","article-title":"Type 1 diabetes mellitus following COVID-19 RNA-based vaccine","volume":"13","author":"Sakurai","year":"2022","unstructured":"Sakurai KNarita DSaito NUeno TSato RNiitsuma STakahashi K & Arihara Z. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. Journal of Diabetes Investigation2022131290\u20131292. (https:\/\/doi.org\/10.1111\/jdi.13781)"},{"key":"bib7","series-title":"Diabetologia","first-page":"1500","article-title":"Type 1 diabetes as an autoimmune disease: the evidence","volume":"57","author":"Paschou","year":"2014","unstructured":"Paschou SAPetsiou AChatzigianni KTsatsoulis A & Papadopoulos GK. Type 1 diabetes as an autoimmune disease: the evidence. Diabetologia2014571500\u20131501. (https:\/\/doi.org\/10.1007\/s00125-014-3229-5)"},{"key":"bib8","series-title":"Retinal Physician","article-title":"Diabe","author":"Barbazetto","year":"2010","unstructured":"Barbazetto IA. Diabetic Retinopathy: the Masqueraders Clinical hallmarks of DR can be associated with a variety of diseases. Retinal Physician2010. Available at https:\/\/www.retinalphysician.com\/issues\/2010\/july-aug\/diabetic-retinopathy-the-masqueraders"},{"key":"bib9","series-title":"New England Journal of Medicine","first-page":"2643","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","unstructured":"Nathan DMCleary PABacklund JYGenuth SMLachin JMOrchard TJRaskin P & Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine20053532643\u20132653. (https:\/\/doi.org\/10.1056\/NEJMoa052187)"},{"key":"bib10","series-title":"New England Journal of Medicine","first-page":"977","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","unstructured":"Nathan DMGenuth SLachin JCleary PCrofford ODavis MRand L & Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine1993329977\u2013986. (https:\/\/doi.org\/10.1056\/NEJM199309303291401)"},{"key":"bib11","series-title":"American Journal of Physiology","first-page":"F716","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","unstructured":"Pichler RAfkarian MDieter BP & Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. American Journal of Physiology2017312F716\u2013F731. (https:\/\/doi.org\/10.1152\/ajprenal.00314.2016)"},{"key":"bib12","series-title":"Nephrology Nursing Journal","first-page":"631","article-title":"Pathophysiology of diabetic nephropathy","volume":"34","author":"Sego","year":"2007","unstructured":"Sego S. Pathophysiology of diabetic nephropathy. Nephrology Nursing Journal200734631\u2013633. (https:\/\/doi.org\/10.1016\/S2211-9477(1270005-5)"},{"key":"bib13","series-title":"Journal of the American Society of Nephrology","first-page":"1358","article-title":"Extracellular matrix metabolism in diabetic nephropathy","volume":"14","author":"Mason","year":"2003","unstructured":"Mason RM & Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. Journal of the American Society of Nephrology2003141358\u20131373. (https:\/\/doi.org\/10.1097\/01.asn.0000065640.77499.d7)"},{"key":"bib14","series-title":"Diabetes Care","first-page":"1643","article-title":"Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010","volume":"39","author":"Leasher","year":"2016","unstructured":"Leasher JLBourne RRAFlaxman SRJonas JBKeeffe JNaidoo KPesudovs KPrice HWhite RAWong TY, Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care2016391643\u20131649. (https:\/\/doi.org\/10.2337\/dc15-2171)"},{"key":"bib15","series-title":"International Journal of Molecular Sciences","first-page":"1816","article-title":"Diabetic retinopathy: pathophysiology and treatments","volume":"19","author":"Wang","year":"2018","unstructured":"Wang W & Lo ACY. Diabetic retinopathy: pathophysiology and treatments. International Journal of Molecular Sciences2018191816. (https:\/\/doi.org\/10.3390\/ijms19061816)"},{"key":"bib16","series-title":"Diabetes, Obesity and Metabolism","first-page":"53","article-title":"Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy","volume":"10","author":"Ejaz","year":"2008","unstructured":"Ejaz SChekarova IEjaz ASohail A & Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes, Obesity and Metabolism20081053\u201363. (https:\/\/doi.org\/10.1111\/j.1463-1326.2007.00795.x)"},{"key":"bib17","series-title":"Diabetes Care","first-page":"556","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","unstructured":"Yau JWYRogers SLKawasaki RLamoureux ELKowalski JWBek TChen SJDekker JMFletcher AGrauslund J, Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care201235556\u2013564. (https:\/\/doi.org\/10.2337\/dc11-1909)"},{"key":"bib18","series-title":"Archives of Ophthalmology","first-page":"527","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years","volume":"102","author":"Klein","year":"1984","unstructured":"Klein RKlein BEMoss SEDavis MD & DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Archives of Ophthalmology1984102527\u2013532. (https:\/\/doi.org\/10.1001\/archopht.1984.01040030405011)"},{"key":"bib19","series-title":"American Journal of Kidney Diseases","first-page":"947","article-title":"Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM","volume":"31","author":"Estacio","year":"1998","unstructured":"Estacio ROMcFarling EBiggerstaff SJeffers BWJohnson D & Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. American Journal of Kidney Diseases199831947\u2013953. (https:\/\/doi.org\/10.1053\/ajkd.1998.v31.pm9631838)"},{"key":"bib20","series-title":"Neurology","first-page":"817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study","volume":"43","author":"Dyck","year":"1993","unstructured":"Dyck PJKratz KMKarnes JLLitchy WJKlein RPach JMWilson DMO'Brien PCMelton LJ & Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology199343817\u2013824. (https:\/\/doi.org\/10.1212\/wnl.43.4.817)"},{"key":"bib21","series-title":"Pharmacology and Therapeutics","first-page":"1","article-title":"Diabetic neuropathy: mechanisms to management","volume":"120","author":"Edwards","year":"2008","unstructured":"Edwards JLVincent AMCheng HT & Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology and Therapeutics20081201\u201334. (https:\/\/doi.org\/10.1016\/j.pharmthera.2008.05.005)"},{"key":"bib22","series-title":"Frontiers in Endocrinology","first-page":"12","article-title":"Impaired axonal regeneration in diabetes. Perspective on the underlying mechanism from in vivo and in vitro experimental studies","volume":"8","author":"Sango","year":"2017","unstructured":"Sango KMizukami HHorie H & Yagihashi S. Impaired axonal regeneration in diabetes. Perspective on the underlying mechanism from in vivo and in vitro experimental studies. Frontiers in Endocrinology2017812. (https:\/\/doi.org\/10.3389\/fendo.2017.00012)"},{"key":"bib23","series-title":"PLoS One","first-page":"e0212574","article-title":"The risk factors for diabetic peripheral neuropathy: a meta-analysis","volume":"14","author":"Liu","year":"2019","unstructured":"Liu XXu YAn M & Zeng Q. The risk factors for diabetic peripheral neuropathy: a meta-analysis. PLoS One201914e0212574. (https:\/\/doi.org\/10.1371\/journal.pone.0212574)"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/4\/EDM22-0406.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2023\/4\/EDM22-0406.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2023\/4\/EDM22-0406.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:08Z","timestamp":1784555288000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":23,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/edm-22-0406","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}